FRAXIN

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C16H18O10
Molecular Weight	370.3081
Optical Activity	UNSPECIFIED
Defined Stereocenters	5 / 5
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

COC1=CC2=C(OC(=O)C=C2)C(O[C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)=C1O

InChI

InChIKey=CRSFLLTWRCYNNX-QBNNUVSCSA-N

InChI=1S/C16H18O10/c1-23-7-4-6-2-3-9(18)25-14(6)15(11(7)20)26-16-13(22)12(21)10(19)8(5-17)24-16/h2-4,8,10,12-13,16-17,19-22H,5H2,1H3/t8-,10-,12+,13-,16+/m1/s1

HIDE SMILES / InChI

Molecular Formula	C16H18O10
Molecular Weight	370.3081
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	5 / 5
E/Z Centers	0
Optical Activity	UNSPECIFIED

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/16264268 | https://www.ncbi.nlm.nih.gov/pubmed/28922728 | https://www.ncbi.nlm.nih.gov/pubmed/15930756

Cortex fraxini, a famous Chinese herbal folk medicine, is used for the clinical treatment of hyperuricemia, arthritis, diarrhea, liver-protective. and bacillary dysentery. Fraxin, a main active component isolated from Cortex fraxini, possesses a variety of bioactivities such as anti-inflammatory, antioxidant, analgesic, antimicrobial, antiviral, immunomodulatory, anti-hyperuricemia and diuresis. And a recent study indicated that fraxin showed potent hepatoprotective effects in vitro and in vivo, presumably through reducing Oxidative Stress. Fraxin protects cells from oxidative stress.

CNS Activity

Approval Year

Targets

Primary Target	Pharmacology	Potency
Oxidative Stress 162 Target ID: WP408 Sources: https://www.ncbi.nlm.nih.gov/pubmed/16264268 \| https://www.ncbi.nlm.nih.gov/pubmed/28383514	Inhibitor 8504
Carbonic anhydrase IX 36 Target ID: CHEMBL3594 Sources: https://www.ncbi.nlm.nih.gov/pubmed/22892213	Inhibitor 8504	0.61 µM [Ki]
Carbonic anhydrase VII 35 Target ID: CHEMBL2326 Sources: https://www.ncbi.nlm.nih.gov/pubmed/22892213	Inhibitor 8504	4.32 µM [Ki]
Carbonic anhydrase I 62 Target ID: CHEMBL261 Sources: https://www.ncbi.nlm.nih.gov/pubmed/22892213	Inhibitor 8504	4.86 µM [Ki]
Carbonic anhydrase XII 30 Target ID: CHEMBL3242 Sources: https://www.ncbi.nlm.nih.gov/pubmed/22892213	Inhibitor 8504	7.7 µM [Ki]

Conditions

Condition	Modality	Targets	Highest Phase	Product
Acute liver injury 3 Sources: https://www.ncbi.nlm.nih.gov/pubmed/28922728 https://www.ncbi.nlm.nih.gov/pubmed/28383514	Primary		Preclinical	Unknown Approved Use Unknown
Hyperuricemia 8 Sources: https://www.ncbi.nlm.nih.gov/pubmed/21620826	Primary		Preclinical	Unknown Approved Use Unknown

PubMed

Title	Date	PubMed
HIV gp41 binding phenolic components from Fraxinus sieboldiana var. angustata.	2002-11	12451497

Patents

Sample Use Guides

In Vivo Use Guide

In mice model, pretreatment with fraxin (10, 20 or 40mg/kg) along with CCl4 significantly alleviated liver damage as indicated by the decreased levels of liver index, liver marker enzymes, lipid peroxidation, inflammatory mediators, increased levels of the antioxidant enzymatic and non-enzymatic defense parameters, and improved hepatic histopathology changes.

Route of Administration: Oral

In Vitro Use Guide

Fraxin showed free radical scavenging effect at high concentration (0.5 mM) and cell protective effect against H2O2-mediated oxidative stress.

Substance Class	Chemical Created by `admin` on `Mon Mar 31 22:21:57 GMT 2025` Edited by `admin` on `Mon Mar 31 22:21:57 GMT 2025`
Record UNII	V7M270Y072
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

7,8-DIHYDROXY-6-METHOXYCOUMARIN 8-.BETA.-D-GLUCOPYRANOSIDE

Preferred Name

English

FRAXIN

Common Name

English

FRAXOSIDE

Common Name

English

2H-1-BENZOPYRAN-2-ONE, 8-(.BETA.-D-GLUCOPYRANOSYLOXY)-7-HYDROXY-6-METHOXY-

Systematic Name

English

FRAXETIN 8-.BETA.-D-GLUCOPYRANOSIDE

Common Name

English

FRAXETOL 8-GLUCOSIDE

Common Name

English

FRAXIN [MI]

Common Name

English

Code System Code Type Description

CAS

524-30-1